Intensive chemotherapy of metastatic colorectal cancer: Weighing between safety and clinical efficacy

Expert Opinion on Biological Therapy

Volumn 11, Issue 6, 2011, Pages 821-824

  Bruera, Gemma ^a   Ricevuto, Enrico ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

FOLFOXIRI bevacizumab; intensive chemotherapy; metastatic colorectal cancer; triplet chemotherapy

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ACUTE HEART INFARCTION; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TARGETING; FEBRILE NEUTROPENIA; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMATITIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS;

EID: 79955845350     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.582462     Document Type: Article

References (10)

1. Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52
2. Bruera G, Santomaggio A, Cannita K, et al. "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer 2010;10:567
3. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-6 (Pubitemid 46797946)
4. Masi G, Vasile E, Loupakis F, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst 2011;103:21-30
5. Souglakos J, Andrulakis N, Syrigos K, et al. FOLFOXIRI (folin acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folin acid, 5-fluorouracil and irinotecan) as first-line treatment in metestatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006;94:798-805
6. Morelli MF, Santomaggio A, Ricevuto E, et al. on behalf of CINBO (Consorzio Interuniversitario Nazionale per la Bio- Oncologia). Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in Advanced Colorectal Cancer: a dose-finding and phase II study. Oncol Rep 2010;23(6):1635-40
7. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary respectability of colorectal liver metastases following preoperative chemotherapy with Cetuximab: the CELIM randomized phase 2 trial. Lancet Oncol 2010;11:38-47
8. Garufi C, Torsello A, Tumolo S, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadiuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010;103(10):1542-7
9. Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005;16(8):1311-19 (Pubitemid 41158476)
10. Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of Bevacizumab. J Natl Cancer Inst 2005;97(3):981-9 (Pubitemid 41430564)